BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Transposagen Biopharmaceuticals, Inc. Receives Over $4.3 Million in Grants and Investment


6/21/2013 9:42:18 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LEXINGTON, Ky., June 21, 2013 /PRNewswire-iReach/ -- Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that it is the recipient of over $2,975,426 in additional Small Business Innovation Research (SBIR) funding; $1,975,426 from the National Institutes of Health (NIH) and $1,000,000 from the KY Cabinet for Economic Development (CED). Transposagen's project titled: Creation of Hyperactive Transposons for Mutagenesis in Rodents will further develop Transposagen's piggyback(TM) DNA Modification System. The piggyBac(TM) technology and other Transposagen technologies, such as site-specific nucleases called XTN(TM) TALENs, are genome modification tools used for the creation of custom cell lines and rat and mouse models.

(Photo: http://photos.prnewswire.com/prnh/20130621/CG36249)

The NIH performs comprehensive external peer review using experts from academia and industry to assess the scientific merit, technical merit, and commercial application of the proposed technology. The following was stated in the NIH's Project Summary Statement, "Transposon mediated mutagenesis has the potential to generate knockout embryonic stem cells and rats for a large number of genes. These are likely to become powerful tools in the researchers' toolkit. Impact on a broad spectrum of research areas is likely to be huge and sustained."

"This most recent award from the NIH and the CED further validates the importance of Transposagen's core technologies," said Dr. Eric Ostertag, CEO of Transposagen Biopharmaceuticals, Inc. "The focus of this grant is the creation of genetically modified rat models for studying human disease. However, Transposagen also provides these technologies to researchers for the creation of nearly any type of genetic modification in any model organism or cell line."

As part of the conditions of the award from the CED, Transposagen was required to match the $1,000,000 grant with at least $1,000,000 in investment money. Transposagen raised over $1.3 million in its Series A investment round, mostly from local angel investors. Transposagen has received grant funding and investments of over $8.0 million since 2005.

About Transposagen Biopharmaceuticals:

Transposagen Biopharmaceuticals, Inc. is a worldwide leader in technologies and services for genetic modification. Transposagen is dedicated to providing better disease models through genetic modification. Transposagen specializes in custom and off-the-shelf XTN(TM) site-specific nucleases, animal models, cell lines, stem cells and cutting-edge research tools and technologies to improve drug discovery and development research.

Contact:
Jack Crawford
535 W. Second Street
Lexington, KY 40508
(315) 351-9115

Media Contact:Jack Crawford, Transposagen Biopharmaceuticals, (315) 351-9115, jcrawford@transposagenbio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Transposagen Biopharmaceuticals, Inc.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES